Psychedelic-assisted therapy is the most rigorously studied new paradigm in mental health treatment in decades. But the gap between the sophistication of the research and the tools available for clinical documentation remains enormous. This post maps the evidence base that every PAT practitioner should know — and explains why MycenAI exists.
The Renaissance in Psychedelic Research
The story of psychedelic science is not a straight line. It is a tale of extraordinary promise, political suppression, and painstaking rehabilitation — one that every clinician entering this field should understand, because the history shapes the regulatory and cultural landscape you will be practising in.
The first wave (1950s–1960s). Between 1950 and 1965, more than 1,000 peer-reviewed papers were published on LSD alone. Researchers at institutions including Harvard, UCLA, and the Saskatchewan Mental Hospital explored psychedelics for alcoholism, depression, end-of-life anxiety, and a range of other conditions. Humphry Osmond coined the term “psychedelic” in 1957. Stanislav Grof conducted hundreds of supervised LSD sessions and developed frameworks for understanding non-ordinary states of consciousness that remain influential today. The early results were promising but methodologically uneven by modern standards — many studies lacked control groups, used inconsistent dosing, and had minimal follow-up.
The scheduling era (1970s–1990s). The Controlled Substances Act of 1970 placed most classical psychedelics into Schedule I in the United States, effectively halting legitimate research. Similar scheduling followed in most Western countries. For roughly three decades, psychedelic science existed primarily in the margins — underground therapeutic communities, ethnobotanical fieldwork, and a handful of researchers who kept the intellectual tradition alive.
The modern renaissance (2000s–present). The current era of psychedelic research began with a series of carefully designed studies that met contemporary standards of scientific rigour. Rick Strassman's DMT research at the University of New Mexico in the 1990s reopened the door. Francisco Moreno's psilocybin study for OCD at the University of Arizona in 2006 was among the first modern clinical trials. But the landmark moment came in 2006 when Roland Griffiths and colleagues at Johns Hopkins published “Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance” in Psychopharmacology — a paper that demonstrated rigorous methodology could be applied to subjective psychedelic experiences.
Today, the field is anchored by world-class research institutions. The Johns Hopkins Center for Psychedelic and Consciousness Research, established in 2019 with $17 million in funding, was the first centre of its kind in the United States. The Imperial College Centre for Psychedelic Research in London, led by Robin Carhart-Harris, has produced some of the most influential neuroimaging studies of psilocybin's effects on brain connectivity. MAPS PBC (the Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation) has driven the MDMA-assisted therapy programme through the FDA regulatory process. NYU Langone Health and Yale University have contributed significant work on psilocybin for depression and alcohol use disorder. And in Australia, the University of Melbourne has emerged as a key hub for psychedelic research in the Asia-Pacific region, contributing to an evidence base that informed Australia's world-first rescheduling of psilocybin and MDMA for therapeutic use in 2023.
MDMA-Assisted Therapy for PTSD
MDMA-assisted therapy for post-traumatic stress disorder represents the most advanced psychedelic therapy programme in the modern regulatory pipeline, and its journey through FDA review has been both groundbreaking and instructive.
The MAPS clinical programme began with Phase 2 trials conducted across multiple sites between 2004 and 2017. These studies consistently demonstrated large effect sizes. In one pivotal Phase 2 study, 61% of participants no longer met diagnostic criteria for PTSD two months after treatment, compared with 25% in the active placebo group. At the 12-month follow-up, 68% of participants in the MDMA group no longer met PTSD criteria.
The Phase 3 programme — the MAPP (MDMA-Assisted Psychotherapy for PTSD) trials — comprised two randomised, double-blind, placebo-controlled studies. MAPP1, published in Nature Medicine in 2021, showed that 67% of participants in the MDMA group no longer met PTSD diagnostic criteria, compared with 32% in the placebo group. The effect size (Cohen's d = 0.91) was substantially larger than those typically seen with SSRIs or trauma-focused CBT. MAPP2 replicated these findings in a more diverse participant population.
The therapy model is as important as the molecule. The MAPP protocol involves approximately 42 hours of therapist contact: 3 preparatory sessions (90 minutes each), 3 medicine sessions (approximately 8 hours each, conducted with a co-therapist dyad), and 9 integration sessions (90 minutes each). This is not a drug-only intervention. The therapeutic relationship, the preparation framework, and the integration process are considered essential components of the treatment. MDMA is understood as a catalyst for therapeutic work — reducing fear responses, increasing empathy and trust, and enabling access to traumatic material that clients have been unable to process through conventional approaches.
Regulatory status. The FDA granted Breakthrough Therapy Designation for MDMA-assisted therapy for PTSD in 2017. In June 2024, however, an FDA advisory committee voted against recommending approval, citing concerns about functional unblinding (participants could often tell whether they received MDMA or placebo), insufficient diversity in trial populations, and questions about the generalisability of results to real-world settings. The FDA subsequently issued a Complete Response Letter, declining to approve the treatment in its current form. MAPS PBC (now operating as Lykos Therapeutics) has been working to address these concerns, and additional trials and data submissions are in progress. The outcome remains uncertain, but the clinical evidence for efficacy has not been disputed — the questions are methodological and regulatory.
For clinicians, the MDMA story illustrates a critical point: even when the evidence is strong, the path to regulatory approval is complex. Understanding this landscape is essential for any practitioner advising clients about treatment options.
Psilocybin for Depression
Psilocybin has emerged as the most extensively studied classical psychedelic for mood disorders, with a growing body of randomised controlled trials demonstrating rapid and durable antidepressant effects.
The Johns Hopkins programme. The 2016 study by Griffiths and colleagues on psilocybin for cancer-related existential distress was a watershed moment — published simultaneously with a parallel study from NYU, both in the Journal of Psychopharmacology. Approximately 80% of participants showed clinically significant decreases in depression and anxiety, with effects sustained at six-month follow-up. A subsequent Johns Hopkins trial published in JAMA Psychiatry in 2020 examined psilocybin-assisted therapy for major depressive disorder in a broader population and found that 71% of participants showed a clinically significant response at four weeks, with 54% meeting criteria for remission.
The Imperial College programme. Robin Carhart-Harris and colleagues conducted the first randomised controlled trial comparing psilocybin therapy with escitalopram (a standard SSRI) for moderate-to-severe major depressive disorder, published in the New England Journal of Medicine in 2021. While the primary outcome measure did not show a statistically significant difference between the two groups, secondary outcomes consistently favoured psilocybin, including greater improvements on the BDI-II (Beck Depression Inventory), higher remission rates, and better scores on measures of well-being, meaning in life, and emotional processing. The study was notable for demonstrating that psilocybin therapy could produce comparable or superior results to a standard antidepressant with just two dosing sessions.
Industry trials. The FDA granted Breakthrough Therapy Designation for psilocybin therapy for treatment-resistant depression in 2018 (to COMPASS Pathways) and in 2019 (to the Usona Institute for major depressive disorder). COMPASS Pathways' Phase 2b trial, the largest psilocybin trial to date with 233 participants, found that a 25mg dose produced significant reductions in depression at three weeks. However, effects attenuated by 12 weeks, raising important questions about dosing frequency and the role of integration support. Usona Institute's Phase 2 trial has shown promising results with a single-dose model paired with more extensive psychological support.
The therapy model across these studies typically involves three phases: preparation (1–2 sessions establishing therapeutic rapport, setting intentions, and providing psychoeducation about the experience), dosing (1–2 sessions of 6–8 hours with trained therapists providing non-directive psychological support), and integration (2–4 sessions helping participants make meaning of and incorporate insights from the experience). The quality of the therapeutic relationship and the integration process are increasingly recognised as key moderators of outcome — a point that has significant implications for how clinicians are trained and supported.
Ketamine-Assisted Psychotherapy
Ketamine occupies a unique position in the psychedelic therapy landscape because it is already legally available. As an FDA-approved anaesthetic, ketamine can be prescribed off-label for psychiatric conditions, and this has led to a rapidly growing — and unevenly regulated — treatment ecosystem.
The evidence base. Ketamine's rapid antidepressant effects were first reported by Berman and colleagues in 2000, and subsequent research has consistently demonstrated that a single sub-anaesthetic dose of IV ketamine can produce significant reductions in depressive symptoms within hours, with effects lasting days to weeks. A 2015 meta-analysis of 7 randomised controlled trials found a large effect size (Cohen's d = 0.99) at 24 hours post-infusion. Esketamine (Spravato), the S-enantiomer of ketamine delivered as a nasal spray, received FDA approval for treatment-resistant depression in 2019.
The distinction between ketamine infusion and ketamine-assisted psychotherapy (KAP) is clinically important. Many IV ketamine clinics operate on a medical model: patients receive infusions in a clinical setting with minimal psychological support, often without preparation or integration sessions. While this approach can produce short-term symptom relief, the effects tend to be transient without ongoing infusions.
KAP, by contrast, embeds the ketamine experience within a psychotherapeutic framework. Preparation sessions establish therapeutic goals and build the alliance. The medicine session itself is supported by a therapist who provides a holding environment and may facilitate exploration of material that arises. Integration sessions help the client process and apply insights. Emerging evidence suggests that this combined approach may produce more durable outcomes than ketamine alone, though the research comparing the two models is still developing.
For clinicians, ketamine-assisted psychotherapy is often the most accessible entry point into psychedelic-assisted practice. It does not require a research licence or special regulatory exemption, and it can be delivered within existing clinical frameworks — though it does demand specialised training, appropriate medical oversight, and careful data security practices.
Other Emerging Areas
Beyond the three major programmes described above, several other psychedelic compounds are generating significant research interest.
Ayahuasca — the Amazonian brew containing DMT and MAO inhibitors — has been studied for depression, substance use disorders, and grief. A small randomised controlled trial by Palhano- Fontes and colleagues (2019) found significant antidepressant effects in treatment-resistant depression. Research is complicated by the brew's variable composition and the cultural context of its traditional use.
LSD-assisted therapy has seen a resurgence of clinical interest. Peter Gasser's study in Switzerland (2014) demonstrated significant reductions in anxiety among patients with life-threatening illness. MindMed has conducted Phase 2 trials for LSD-assisted therapy for generalised anxiety disorder, with encouraging preliminary results. LSD's long duration (8–12 hours) and potency present unique clinical considerations.
Ibogaine, a naturally occurring compound from the African iboga plant, has shown remarkable preliminary results for opioid use disorder. Observational studies report that a single ibogaine session can dramatically reduce withdrawal symptoms and cravings. However, ibogaine carries significant cardiovascular risks, and clinical development requires careful medical screening and cardiac monitoring. A 2024 study of ibogaine combined with magnesium in veterans with traumatic brain injury showed significant improvements across multiple outcome measures.
5-MeO-DMT, a short-acting tryptamine found in the secretions of the Sonoran Desert toad (Bufo alvarius) and various plant sources, is being investigated for treatment-resistant depression and substance use disorders. Its brief duration (15–45 minutes) and often intense experiential profile present both clinical advantages and challenges. Research remains in early stages.
Each of these compounds has a distinct pharmacological profile, experiential character, and risk profile. For clinicians, the key takeaway is that psychedelic-assisted therapy is not a monolithic field — it encompasses a range of substances, protocols, and therapeutic approaches, each requiring specific knowledge and modality-specific clinical competencies.
Key Therapeutic Modalities in PAT
One of the most important — and least discussed — aspects of psychedelic-assisted therapy is that it does not exist in a therapeutic vacuum. PAT practitioners draw on established psychotherapeutic modalities, adapting them for the unique demands of psychedelic states. Understanding which frameworks are being used and how they are adapted is essential for competent practice and accurate clinical documentation.
Internal Family Systems (IFS). Richard Schwartz's parts-based model has become one of the most widely adopted frameworks in psychedelic therapy. During psychedelic states, clients frequently report spontaneous encounters with distinct “parts” of themselves — protectors, exiles, and managers — that align naturally with IFS theory. The psychedelic experience can facilitate direct access to exiled parts that carry traumatic material, and the IFS framework provides a structured approach for working with this material safely. Integration sessions using IFS help clients understand and consolidate parts work that occurred during the medicine session.
Somatic Experiencing (SE). Peter Levine's body-oriented approach to trauma resolution is particularly relevant in PAT because psychedelic experiences frequently involve intense somatic phenomena — trembling, temperature changes, muscular tension and release, and spontaneous movement. Therapists trained in SE can help clients track and complete somatic trauma responses that emerge during medicine sessions, rather than defaulting to cognitive processing. This is especially valuable for clients whose trauma is stored primarily in the body and who have not responded to talk-based therapies.
Acceptance and Commitment Therapy (ACT). ACT's emphasis on psychological flexibility, acceptance, and values-aligned action maps well onto the psychedelic therapy framework. The concept of “cognitive defusion” — learning to observe thoughts without being controlled by them — parallels the observer perspective that many people describe during psychedelic experiences. ACT-informed integration helps clients translate psychedelic insights into concrete, values-driven behavioural change. The overlap between ACT and psychedelic therapy has been explored in detail by researchers including Luoma and colleagues.
Transpersonal psychology. Stanislav Grof's work remains foundational here. Transpersonal approaches provide a framework for understanding mystical, spiritual, and existential experiences that frequently occur during psychedelic sessions — and that can be therapeutically significant. Practitioners using a transpersonal lens are equipped to work with ego dissolution, experiences of unity, encounters with archetypal material, and shifts in ontological worldview that may be deeply meaningful to clients but fall outside the scope of conventional diagnostic frameworks.
Psychodynamic and attachment-based approaches. Psychedelic experiences often surface unconscious material — early memories, attachment patterns, relational dynamics with caregivers — in vivid and emotionally charged form. Psychodynamically informed therapists can work with transference and countertransference dynamics that are amplified during medicine sessions, and can help clients understand how early relational patterns are shaping their current difficulties. The extended therapeutic relationship in PAT protocols (preparation through integration) provides a relational container that is well-suited to psychodynamic work.
In practice, many PAT clinicians work integratively, drawing on multiple modalities depending on what emerges in session. This flexibility is a strength, but it also creates documentation challenges — how do you accurately record a session that moved between IFS parts work, somatic processing, and transpersonal exploration? The treatment planning frameworks used in conventional therapy often struggle to accommodate this kind of multidimensional clinical work.
Outcome Measures in PAT Research
The psychedelic therapy research literature employs a specific set of validated instruments that clinicians working in this field should be familiar with. These measures serve two functions: they are the tools used in clinical trials to evaluate efficacy, and they are increasingly being adopted by practitioners to track outcomes in clinical settings.
Measures of the psychedelic experience itself:
- MEQ30 (Mystical Experience Questionnaire). A 30-item self-report measure assessing four domains: mystical (internal and external unity, noetic quality, sacredness), positive mood, transcendence of time and space, and ineffability. The MEQ30 is significant because scores on this measure consistently predict long-term therapeutic outcomes — the degree of mystical experience correlates with the magnitude of clinical improvement. This has profound implications for clinical practice: the quality of the subjective experience matters, which means that set, setting, and therapeutic support are not peripheral concerns but central determinants of efficacy.
- 5D-ASC (Five-Dimensional Altered States of Consciousness Questionnaire). A comprehensive 94-item (or 11-item short form) measure assessing five dimensions: oceanic boundlessness, anxious ego dissolution, visionary restructuralisation, auditory alterations, and vigilance reduction. The 5D-ASC provides a more granular phenomenological profile of the psychedelic experience than the MEQ30 and is widely used in European research programmes.
Symptom and diagnostic measures:
- PCL-5 (PTSD Checklist for DSM-5). The standard self-report measure for PTSD symptom severity, used as a primary outcome in the MAPS MDMA trials. Scores range from 0 to 80, with a score of 31–33 typically used as the diagnostic cut-off.
- BDI-II (Beck Depression Inventory, Second Edition). A 21-item self-report measure of depression severity, widely used across psilocybin depression trials. Scores range from 0 to 63.
- QIDS-SR (Quick Inventory of Depressive Symptomatology, Self-Report). A 16-item measure of depression used as a primary outcome in several psilocybin trials, including the Imperial College escitalopram comparison study.
- GAD-7 (Generalised Anxiety Disorder 7-Item Scale). A brief screening and severity measure for generalised anxiety, frequently used as a secondary outcome across psychedelic therapy trials.
Why these matter for practitioners. If you are delivering psychedelic-assisted therapy — or any therapy informed by psychedelic research — you should be using validated outcome measures to track client progress. This is not just good clinical practice; it is essential for building the evidence base, supporting insurance and regulatory conversations, and demonstrating the effectiveness of your work. The challenge is that most clinical documentation systems were not designed with these instruments in mind. Recording a PCL-5 score is straightforward; contextualising it alongside an MEQ30 profile and a detailed account of a medicine session is not.
The Documentation Gap
Here is the paradox at the heart of psychedelic-assisted therapy in 2026: the research has never been more rigorous, the therapeutic models have never been more sophisticated, and yet there are no standardised clinical documentation frameworks designed specifically for PAT practice.
Consider what a PAT clinician needs to document across a full treatment arc. Preparation sessions require detailed notes on informed consent (which includes substance-specific risk disclosures), medical screening, intention-setting, and psychoeducation. Medicine sessions — which can last 6 to 8 hours and involve a co-therapist dyad — generate complex clinical material that spans somatic, emotional, cognitive, relational, and sometimes transpersonal domains. Integration sessions must connect the experiential material from the medicine session to ongoing therapeutic goals, track symptom change, and document any adverse effects or challenging experiences.
This is documentation that does not fit neatly into a conventional clinical note format. A standard progress note template — whether SOAP, BIRP, or DAP — was designed for a 50-minute therapy hour, not an 8-hour medicine session involving two therapists, a non-ordinary state of consciousness, and clinical material that moves fluidly between modalities. The documentation burden is already the leading cause of clinician burnout in conventional practice; in PAT, the burden is compounded by the sheer complexity and volume of material that needs to be recorded.
This gap has real consequences. Clinicians working without PAT-specific documentation frameworks are more likely to produce notes that are either insufficiently detailed (creating clinical and legal risk) or so lengthy and unstructured that they fail to serve their core functions — continuity of care, clinical decision-making, and communication with other providers. Supervisors reviewing PAT cases often lack standardised benchmarks for evaluating documentation quality. And the field as a whole lacks the aggregated, structured clinical data that would support practice-based evidence development.
MycenAI's Clinical Prompt Library is designed to close this gap. We are building AI-assisted documentation tools that understand the structure and language of psychedelic-assisted therapy — preparation, medicine sessions, integration, adverse event tracking, outcome measurement, and the specific therapeutic modalities used in PAT practice. These tools are designed to help clinicians produce thorough, structured, clinically defensible documentation without the hours of administrative work that currently follows every medicine session.
The goal is not to replace clinical judgment. It is to give clinicians tools that match the sophistication of the therapy they are delivering — tools that understand what a preparation note should contain, how to document a medicine session that spanned IFS work and somatic processing, and how to track outcomes across a multi-session treatment arc. Documentation should support the clinical work, not compete with it for the clinician's time and attention.
If you are a licensed clinician working in psychedelic-assisted therapy — or preparing to — we invite you to explore the Clinical Prompt Library at confideai.ai. The research foundations are strong. The therapeutic models are mature. It is time the documentation caught up.